A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTempus AI
About this trial
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Eligibility criteria
Qualifiers
≥18 years of age
Willing and able to provide informed consent
Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies
Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy
Disqualifiers
Non-squamous histologies (eg, nasopharynx or salivary gland)
Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy
Tumors that are PD-L1 negative (CPS <1)
Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupSponsors and collaborators
Tempus AI
Lead sponsor
AstraZeneca
Collaborator
Source ClinicalTrials.gov